



Tridecaptins: An undershadowed class of antibiotics to combat colistin- and multidrug-resistant Enterobacteriaceae

Hemraj Nandanwar

Clinical Microbiology and Bioactive Screening Laboratory, CSIR-Institute of Microbial Technology, India

Abstract:

The emergence of extremely drug-resistant and pan drug-resistant strains of Enterobacteriaceae worldwide demands the immediate discovery and development of new antibiotics. The present study discusses the antimicrobial potential of tridecaptin M, a new member of this old family of antibiotics, isolated from a mud bacterium *Paenibacillus* sp. M-152. Tridecaptin M displayed strong antibacterial activity (MICs of 2 to 8 µg/ml) against clinical strains of *Klebsiella pneumoniae* (which were resistant to colistin, carbapenems, third- and fourth-generation cephalosporins, fluoroquinolones, fosfomycin, and other antibiotics) and mcr-1-positive *Escherichia coli* strains. The compound exhibited negligible acquired resistance, low in vitro cytotoxicity and hemolytic activity, and no significant acute toxicity in mice. It also showed promising efficacy in a thigh infection model of colistin-resistant *K. pneumoniae*. The in vitro kinetic studies revealed that tridecaptin M at a concentration of 16 µg/ml eradicated the bacteria completely in high cell-density culture. This class of antibiotics possesses a distinct mechanism of action than polymyxin or other antibiotics in the market; hence the chances of cross-resistance are negligible. Altogether, the study demonstrated that tridecaptins are an excellent drug candidate against drug-resistant bacteria. Further studies on safety assessment and PK/PD analysis are required. The study also explains how microbial metabolites could provide a solution to tackle the antibiotic-resistance in superbugs.

Biography:

Dr. Nandanwar has completed his PhD in 2008 from Panjab University, Chandigarh (India) and continued his research in antibiotic discovery from bio-diversity. He is



actively working on management of antibacterial resistance through alternative approach as well as discovering new antibiotics. He is the Senior Principal Scientist, at a premier Indian institute, CSIR-Institute of Microbial Technology, Chandigarh.. He has published more than 25 papers in reputed journals and also filed patent applications for translation of technology.

Recent Publications:

1. Cell-Penetrating Peptide and Antibiotic Combination Therapy: A Potential Alternative to Combat Drug Resistance in Methicillin Resistant *Staphylococcus aureus*
2. Synthesis and antibacterial activity of ricinoleic acid glycosides
3. NorA efflux pump inhibitory activity of coumarins from *Mesua ferrea*
4. 7-Hydroxy-(E)-3-phenylmethylene-chroman-4-one analogues as efflux pump inhibitors against *Mycobacterium smegmatis* mc2 155
5. Phenylpropanoids of *Alpinia galanga* as efflux pump inhibitors in *Mycobacterium smegmatis* mc2155

3rd World Congress on Antibiotics | June 22-23, 2020 | Zurich, Switzerland

Citation: Hemraj Nandanwar; Tridecaptins: An undershadowed class of antibiotics to combat colistin- and multidrug-resistant Enterobacteriaceae; Antibiotics 2020; June 22-23, 2020; Zurich, Switzerland.